- JP-listed companies
- SanBio Company Limited
- Income statement
SanBio Company Limited (4592) Income statement
Market cap
¥143B
P/E ratio
-27.5x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
| 2014/01 | 2015/01 | 2016/01 | 2017/01 | 2018/01 | 2019/01 | 2020/01 | 2021/01 | 2022/01 | 2023/01 | 2024/01 | 2025/01 | 2026/01 | |
| Revenue | 204 | 3,229 | 1,175 | 950 | 491 | 742 | 447 | - | - | - | - | - | - |
| Revenue growth (%) | - | - | - | - | - | - | - | ||||||
| Operating margin (%) | - | - | - | - | - | - | - | ||||||
| Operating income | - | 2,249 | -1,125 | -1,932 | -4,378 | -3,734 | -5,486 | -5,802 | -6,621 | -7,899 | -4,540 | -3,516 | -3,794 |
| Income before tax | -587 | 2,229 | -1,172 | -2,166 | -3,948 | -2,920 | -5,147 | -6,530 | -4,580 | -4,699 | -2,825 | -3,022 | -4,291 |
| Pretax margin (%) | -287.4 | 69 | -99.8 | -228.1 | -804.8 | -393.7 | -1,150.8 | - | - | - | - | - | - |
| Provision for income taxes | - | 492 | -184 | -331 | 1 | 1 | 1 | 174 | 117 | 862 | 102 | -128 | -449 |
| Effective tax rate (%) | - | ||||||||||||
| Net income | -589 | 1,736 | -988 | -1,835 | -3,940 | -2,921 | -5,158 | -3,386 | -4,678 | -5,560 | -2,644 | -2,883 | -3,408 |
| Earnings per share | -15.41 | 44.31 | -22.67 | -40.88 | -86.85 | -60.17 | -100.91 | -65.38 | -90.33 | -95.99 | -40.48 | -41.86 | -52.55 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - |